Stockscreener 앱 받기
0.82
3.24%
-0.0275
시간 외 거래:
.83
0.01
+1.22%
전일 마감가:
$0.8475
열려 있는:
$0.82
하루 거래량:
3.46M
Relative Volume:
0.52
시가총액:
$182.06M
수익:
$2.04M
순이익/손실:
$-43.21M
주가수익비율:
-3.9671
EPS:
-0.2067
순현금흐름:
$-105.93M
1주 성능:
+16.33%
1개월 성능:
+21.37%
6개월 성능:
-51.48%
1년 성능:
-42.66%
1일 변동 폭
$0.795
$0.8374
1주일 범위
$0.6765
$0.8511
52주 변동 폭
$0.5469
$2.93
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.82 | 188.16M | 2.04M | -43.21M | -105.93M | -0.2067 |
VRTX
Vertex Pharmaceuticals Inc
|
423.24 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.19 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Barclays | Overweight |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte regains ex-US rights to Symvess from Fresenius Medical Care - MSN
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Humacyte stock price target reiterated at $3 by H.C. Wainwright - Investing.com Canada
Barclays Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in June - Yahoo Finance
Humacyte (HUMA) price target decreased by 31.82% to 5.46 - MSN
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Humacyte (NASDAQ: HUMA) 2026 proxy adds share increase vote - Stock Titan
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte Q4 2025 earnings preview - MSN
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 - The Manila Times
Humacyte webcast tackles dialysis access with Phase 3 results due - Stock Titan
Humacyte Expands Commercial and Business Development Opportunities through Realignment of Ex-U.S. Rights to Symvess - marketscreener.com
Humacyte (HUMA) takes ex-U.S. Symvess control as Fresenius retains 8.4% stake - Stock Titan
Humacyte Stock (HUMA) Opinions on Symvess Rights Realignment - Quiver Quantitative
Humacyte regains ex-U.S. rights to Symvess from Fresenius By Investing.com - Investing.com Australia
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc.HUMA - PR Newswire
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Humacyte Is Maintained at Buy by D. Boral Capital - Moomoo
Humacyte gets global rights to Symvess from Fresenius (HUMA) - Seeking Alpha
FMS Partners with Humacyte to Restructure Symvess Distribution R - GuruFocus
Humacyte Realigns Ex-U.S. Rights to Symvess with Fresenius Medical Care to Accelerate International Commercial Expansion - Minichart
Humacyte Regains Global Rights to Symvess Vascular Graft - TipRanks
Humacyte Marketing Authorization for Symvess acellular vessel accepted by Israel Ministry of Health - Traders Union
Biotechnology company Humacyte, Inc. announces exclusive distribution rights for the innovative medical device Symvess outside the United States. - Bitget
Humacyte regains ex-U.S. rights to Symvess from Fresenius - Investing.com
Humacyte (Nasdaq: HUMA) regains ex-U.S. Symvess rights from Fresenius - Stock Titan
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess® - The Manila Times
HUMA Should I Buy - Intellectia AI
Humacyte shares sink as it announces pricing of $60M direct offering - MSN
Humacyte shares plunge after announcing $60 million registered direct offering - MSN
Humacyte appoints Jim Mercadante as chief commercial officer By Investing.com - Investing.com Australia
HUMA (Humacyte Inc.) shares rise 3.8 percent after 2025 fourth quarter earnings narrowly top analyst expectations.Expert Verified Trades - Cổng thông tin điện tử tỉnh Tây Ninh
Humacyte appoints Jim Mercadante as chief commercial officer - Investing.com
Humacyte Appoints Jim Mercadante as Chief Commercial Officer - Yahoo Finance
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.10%
자본화:
|
볼륨(24시간):